Study of the Main Pharmacokinetic Parameters of Pharmacological Substance - Rapitalam

Natalya V. Avdeeva; Mikhail V. Pokrovskii

Study of the Main Pharmacokinetic Parameters of Pharmacological Substance - Rapitalam

Natalya V. Avdeeva, Mikhail V. Pokrovskii

Abstract

The study was performed on rabbits and rats. The aim of this research was to study Rapitalam pharmacokinetics, excretion and organ distribution in animals. The main method used was the analysis of Rapitalam concentration in animal blood plasma
by means of the previously developed method of highly effective liquid chromatography together with mass selective detecting which is highly sensitive and selective, thus allowing to determine low concentrations of the drug in rabbit various biological
matrixes. Rapitalam concentration in organ gomogenates and excrements was estimated by means of standard curves, then the concentration was recalculated to mg/kg tissue taking into account dilutions. The obtained results showed that decrease
of Rapitalam concentration in blood plasma of the studied animals is quick and has bioexponential character. It was also found that Rapitalam rather intensively penetrates organs and tissues with a high level of haemocirculation. The most part of the drug is eliminated in an invariable form with faeces.

Keywords

Rapitalam, Parkinson’s disease, rabbit blood plasma, highly effective liquid chromatography, pharmacokinetics, metabotrop glutamate receptors

Full Text:

References

Obeso JA, Rodríguez-Oroz MC, Benitez-Temino B, Blesa FJ, Guridi J, Marin C, et al. Functional organization of the basal ganglia: therapeutic implications for Parkinson’s disease. Mov Disord. 2008;23 Suppl 3:S548–S559.

Chaudhuri KR, Healy DG, Schapira AH; National Institute for Clinical Excellence. Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol. 2006;5:235–245.

Litvin?nko I.V. Bol?zn Parkinsona. M.: Miklosh, 2006. 216 s.

4. Johnson KA, Conn PJ, Niswender CM. Glutamate receptors as therapeutic targets for Parkinson’s disease. CNS Neurol Disord Drug Targets. 2009;8:475–491.

Schapira AH. Etiology and pathogenesis of Parkinsons disease. Neurol Clin. 2009;27:583–603.

Chen JJ, Swope DM. Pharmacotherapy for Parkinson’s disease. Pharmacotherapy. 2007;27:161S–173S.

Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinsons disease (2009). Neurology. 2009;72:S1–S136.

Kryzhanovsky GN, Karaban IN, Magaeva SV, Kucheryanu VG, Karaban NV. Parkinson disease (etiology, pathogenesis, clinic, diagnostics, treatment, prevention). 2002:315.

Avdeeva NV, Nikitina VA, Kochkarova IS, Litvinova AS. The possibility of administration of glutamate receptors antagonists in the treatment of parkinson’s disease. Res Result Pharmacol Clin Pharmacol. 2016;2:86–94.

Stacy M, Galbreath A. Optimizing long-term therapy for Parkinson disease: levodopa, dopamine agonists, and treatment-associated dyskinesia. Clin Neuropharmacol. 2008;31:51–56.

Walter BL, Vitek JL. Surgical treatment for Parkinson’s disease. Lancet Neurol. 2004;3:719–728.

Przedborski S. Pathogenesis of nigral cell death in Parkinson’s disease. Parkinsonism Relat Disord. 2005;11Suppl 1:S3–S7.

DeLong MR, Wichmann T. Circuits and circuit disorders of the basal ganglia. Arch Neurol. 2007;64:20–24.

Karaban IN. Use of glutamate receptor blocker amantadine in neurology. Int Neurol J. 2012;2:195–201.

Kravchenko DV, Avdeeva NV, Korokin MV. Assessment of the DNA damage level in peripheral blood leukocytes of mice treated orally with Rapitalam in acute and therapeutic doses. Res Result Pharmacol Clin Pharmacol. 2016;2:9–11.

Conn PJ, Battaglia G, Marino MJ, Nicoletti F. Metabotropic glutamate receptors in the basal ganglia motor circuit. Nat Rev Neurosci. 2005;6:787–798.

Lundblad M, Andersson M, Winkler C, Kirik D, Wierup N, Cenci MA. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson’s disease. Eur J Neurosci. 2002;15:120–132.

Avdeeva NV, Kulikov AL, Pokrovskii MV, Avtina TV. Pharmacokinetic studies of new antiparkinsonian drug Rapitalam. Res Result Pharmacol Clin Pharmacol. 2016;2:3–8.

V. Makarov, Makarov, MN, IA Proskurina, AN Bogdanov, Dmitry Somov Guidelines for preclinical study of medicinal products for the correction of diabetes, obesity and metabolic syndrome, In.:Guidelines for preclinical studies of drugs. Part one. M. Grief and K, 2012. 944.

Guideline on bioanalytical method validation (European medicines agency). Committee for Medicinal Products of Human Use (CHMP), London, July 2011.

Guidance for Industry: Bioanalytical method validation. U. S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evolution and Research (CDER), U. S. Government Printing Office, Washington, DC (2001)

Buzov AA, Kulikov AL, Avtina TV, Pokrovskii MV, Osipova OA. Development and validation of methods of quantitative determination of the new antidiabetic drug in the blood plasma of rats by high performance liquid chromatography with mass spectrometric detection. Res Result Pharmacol Clin Pharmacol. 2016;2:52–57.

Galenko-Yaroshevsky PA, Kulikov AL, Vinakov DV, Avtina TV, Suzdalev KF, Pokrovskii MV. Pharmacokinetic studies derived indole SS-68 with antiarrhythmic and antianginal properties. Res Result Pharmacol Clin Pharmacol. 2016;2:20–24.

Refbacks

There are currently no refbacks.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Journal of Pharmaceutical and Biomedical Sciences